Terns Pharmaceuticals, Inc.
- TERN
- NASDAQ
- Biotechnology
- NASH/Obesity Therapies
- Small-Molecule Drugs
$52.95
Today −0.03%Quote May 15, 2026, 08:00 PM UTC
+0.63%over the last month
Max drawdown −0.2%From 1-month high 0.0%3 months +46.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
59
Market value
$4.93B
Approximate share count
Floor
$52.81
0.3% below price
Resistance
$52.96
0.0% above price
Price vs analyst targets
16 analysts
Lowest target
$14.00Highest target
$70.00
$14.00Highest target
$70.00
- Price $52.95
- Average target $51.40
- Analysts' target range
Analysts' average target sits about 3% lower. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TERNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free